Foundayo is a once-daily pill classified as an oral small-molecule GLP-1 receptor agonist, with a different chemical structure from injectable GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and from oral semaglutide (Rybelsus, the Wegovy pill), which belongs to the same peptide class as the injectables
Event: Novo Nordisk & Eli Lilly Outline Plan to Counter Plaintiff Claims Date: May 19, 2024 Notes: Novo Nordisk and Eli Lilly recently crafted a defendant statement describing their plan to counter plaintiff claims and reduce liability
Looking for a convenient way to support your body's functions with a single dietary supplement during your weight-loss journey
the study revealed people who lived in underserved health regions were less likely to complete 12 weeks of treatment
Never adjust the dose without medical supervision
By indication, the obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period